Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label rollover study of sacituzumab govitecan in metastatic solid tumors
2019-004868-22Phase 3Active
- Sponsor
- Gilead Sciences
- Start
- Jun 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sacituzumab govitecan in Metastatic solid neoplasm and Neoplasm, sponsored by Gilead Sciences. Primary endpoint: Long-term safety outcomes. Started Jun 2020; status: active.
02
Drugs
sacituzumab govitecan
03
Conditions
Metastatic solid neoplasmNeoplasm
Beyond the preview
Go deeper on 2019-004868-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004868-22.